Related Experiment Video

Updated: Jul 13, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial

Jan Ruta1, Paweł Ptaszyński, Marek Maciejewski

  • 1Klinika Kardiologii I Katedry Kardiologii i Kardiochirurgii, Uniwersytetu Medycznego w Lodzi. rutajan@interia.pl

Przeglad Lekarski
|July 24, 2007
PubMed

Insights

Spironolactone did not reduce mortality in patients with severe left ventricular dysfunction after myocardial infarction. This study found no significant benefit in reducing all-cause mortality over 24 months.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Spironolactone, a mineralocorticoid receptor antagonist, is established for chronic heart failure but its role in post-myocardial infarction (post-MI) left ventricular dysfunction was unclear.
  • Severe left ventricular dysfunction (ejection fraction < 30%) post-MI represents a high-risk population.
  • Evaluating spironolactone's impact on mortality in this specific cohort is crucial for treatment guidelines.

Purpose:

  • To assess the effect of spironolactone on all-cause mortality in survivors of acute myocardial infarction with severely depressed ejection fraction (< 30%).
  • To determine if long-term spironolactone treatment impacts 24-month mortality in this patient group.

Summary:

  • A 24-month observational study included 47 patients with severe post-MI left ventricular dysfunction (EF < 30%).
  • 22 patients received spironolactone (25-50 mg/day), while 25 did not.
  • Overall mortality was 40% (19/47); 50% in the spironolactone group versus 32% in the control group, a non-significant difference.

Impact:

  • Long-term spironolactone treatment (25-50 mg/day) did not demonstrate a significant reduction in all-cause mortality in patients with severe post-MI left ventricular dysfunction.
  • Findings suggest that current spironolactone dosages may not be sufficient or effective for improving survival in this high-risk post-MI population.
  • Further research may be needed to explore alternative dosages or patient subgroups where spironolactone could offer benefits.
Abstract

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...